What is transfusion‑related acute lung injury (TRALI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Transfusion-Related Acute Lung Injury (TRALI)?

Transfusion-related acute lung injury (TRALI) is a life-threatening complication characterized by acute respiratory distress and hypoxia that develops within 6 hours of blood transfusion, manifesting as acute lung injury without cardiogenic pulmonary edema. 1

Clinical Definition and Presentation

TRALI presents with:

  • Acute onset of dyspnea, tachypnea, and hypoxia within 6 hours of transfusion
  • Bilateral pulmonary infiltrates on imaging
  • Absence of circulatory overload or other alternative causes of acute lung injury 2

The syndrome requires distinguishing from other causes of acute respiratory distress including sepsis, ARDS from other etiologies, transfusion-associated circulatory overload (TACO), and bacterial contamination 2.

Updated Classification System

The 2019 consensus redefinition eliminated the term "possible TRALI" and introduced a clearer classification 1:

  • TRALI Type I: Occurs in patients WITHOUT pre-existing ARDS risk factors
  • TRALI Type II: Occurs in patients WITH ARDS risk factors or mild existing ARDS

This distinction is clinically important because Type II patients have underlying conditions that predispose them to lung injury, making diagnosis more challenging but no less critical.

Pathophysiology: The Two-Hit Model

TRALI develops through two primary mechanisms 3, 4:

Immune-mediated TRALI (the better understood pathway):

  • Passive transfer of anti-HLA or anti-neutrophil antibodies from donor blood
  • These antibodies react with recipient leukocyte antigens
  • Triggers complement-mediated neutrophil activation and pulmonary sequestration
  • Results in endothelial damage and capillary leak

Non-immune-mediated TRALI (less well understood):

  • Involves biologic response modifiers in stored blood products
  • Includes lipids and CD40 ligand that accumulate during storage
  • Activates sequestered neutrophils in primed patients

The two-event model explains why not all patients develop TRALI 4:

  1. First event: Patient's underlying clinical condition causes pulmonary endothelial activation and neutrophil sequestration
  2. Second event: Transfusion delivers the trigger (antibodies or bioactive substances) that activates these primed neutrophils

Epidemiology and Risk

Based on prospective surveillance data, TRALI occurs at a rate of 0.81 per 10,000 transfused blood components (8.1 per 100,000 components) 5. Despite mitigation strategies, TRALI remains among the leading causes of transfusion-related mortality in developed countries 1, 6.

High-risk populations include patients with 7:

  • Congestive heart failure
  • Chronic liver disease
  • Shock states
  • Current smoking

Clinical Diagnosis

TRALI remains a clinical diagnosis and does NOT require detection of cognate white blood cell antibodies 1. This is a critical point—you diagnose based on clinical presentation and temporal relationship to transfusion, not laboratory confirmation of antibodies.

The diagnosis requires:

  • Temporal relationship: symptoms within 6 hours of transfusion
  • Clinical findings: acute hypoxia, bilateral infiltrates, no evidence of volume overload
  • Exclusion of alternative diagnoses

Management Approach

Immediate supportive care is the cornerstone 2:

  • Stop the transfusion immediately
  • Provide supplemental oxygen or mechanical ventilation as needed
  • Hemodynamic support with vasopressors if hypotension develops
  • Avoid diuretics (this distinguishes management from TACO)

Most patients who survive the acute phase recover completely, though the acute mortality risk is significant 2.

Prevention Strategies

The most effective approach is prevention through donor selection 6, 3:

Blood collection facilities now preferentially use:

  • Male donors for plasma-containing products
  • Female donors who have never been pregnant
  • Female donors tested negative for HLA antibodies

These strategies have successfully reduced TRALI incidence, particularly immune-mediated cases, though the syndrome remains a clinical concern 6.

Critical Reporting Requirement

All cases of suspected TRALI must be immediately reported to the transfusion service 1. This allows for:

  • Investigation of the implicated blood products
  • Testing of donor antibodies
  • Prevention of future cases from the same donor
  • Proper classification and surveillance

The distinction between TRALI, TACO, and other causes of post-transfusion respiratory distress has significant implications for donor management and future transfusion safety.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.